Peptide AOD 9604: Truth About Fat Loss, Benefits & Side Effects

AOD 9604 is sold as a fat-loss peptide. Its development as an obesity drug was reported to have ended after a large trial failed to show it worked (6). This page covers what it is, what the trials found and where it stands with FDA and WADA.

It lists no doses. None of the six trials in the developer’s safety summary tested subcutaneous injection.

What is AOD 9604?

AOD 9604 is a synthetic peptide. It’s Tyr-hGH177-191, a 16-amino-acid fragment from the tail end of human growth hormone, with a tyrosine added at the front (1). Researchers at Monash University in Australia studied it as a synthetic version of growth hormone’s fat-breaking (lipolytic) domain (3).

Human growth hormone affects fat metabolism, muscle growth and blood sugar. In cell assays, AOD 9604 didn’t bind the growth hormone receptor or cause cell proliferation. In obese mice, unlike growth hormone, it didn’t raise blood sugar (2).

It isn’t an FDA-approved drug.

How AOD 9604 works

The mechanism is unsettled. Many sites say it works through the beta-3 adrenergic receptor. The primary paper says otherwise.

In obese mice treated for 14 days, AOD 9604 reduced body weight and body fat. In mice lacking the beta-3 receptor, long-term treatment failed to change body weight. But in an acute experiment it still raised energy expenditure and fat oxidation in those mice. The authors concluded its fat-burning actions “are not mediated directly through the beta(3)-AR” (4).

In obese Zucker rats, daily oral doses for 19 days cut weight gain by more than half (3). Those are animal results. They don’t show how it behaves in people.

Clinical trials: the full story

AOD 9604 was developed by Metabolic Pharmaceuticals in Australia. In 2013 the company’s team published a summary of six randomized, double-blind, placebo-controlled trials in about 900 adults. Two used IV infusions. Four used oral capsules or tablets (1).

Two were Phase IIb obesity trials. One ran 12 weeks in about 300 obese adults, and the other ran 24 weeks in 502 (1).

For the 12-week trial, a 2004 trade-press report said the best-performing group lost 2.8 kg on average. The company said the primary analysis wasn’t statistically significant (p=0.1) and pointed to a secondary analysis instead (5).

The 2013 safety paper doesn’t report the weight results from either obesity trial (1). A 2013 news report said the company stopped developing AOD 9604 in 2007 after a large trial of tablets failed to show it worked (6).

So the honest summary is short. There’s a safety record from short, company-run trials. There’s no demonstrated fat-loss benefit in people.

What the safety evidence shows

The summary paper found no significant change in IGF-1 and no negative effect on glucose tolerance compared with placebo. It detected no antibodies against AOD 9604 in the subset of patients tested. Headache was among the most common adverse events (1).

Serious adverse events did occur. The paper’s abstract says none was related to AOD 9604, but the text reports one that the investigator judged possibly related: diarrhoea at 54 mg in a 17-person single-dose oral study (1). In the 12-week trial, five people had them. Three were in one dose group (two skin cancers and a lipoma), one had a melanoma and one had breast cancer. The principal investigator judged none related to the drug. In the 24-week trial, 18 people (3.6%) had serious events, spread across all groups, including 8 on placebo (1).

Keep the source in mind. The developer paid for all six trials. One author was the company’s former medical director, and another held a 6.9% stake in its parent company (1). That isn’t independent evidence. A 2014 safety paper co-written by the company’s CEO covers animal studies only (8).

FDA lists AOD-9604 among withdrawn bulk-drug nominations. It says it found no or only limited safety-related information, and that it has identified serious adverse events that may be associated with AOD-9604, though causality isn’t clear (7).

Anyone with a cancer history, or who is pregnant or breastfeeding, should talk to a clinician before using any unapproved compound.

AOD 9604 vs semaglutide and tirzepatide

GLP-1 drugs have large trials showing weight loss. AOD 9604 doesn’t.

Compound	Best human weight-loss evidence	FDA approved	How it works
AOD 9604	The developer’s safety paper reports no weight-loss result (1)	No	Unsettled (4)
Semaglutide (Wegovy)	14.9% body weight vs 2.4% on placebo at 68 weeks, 1,961 adults (11)	Yes	GLP-1 receptor agonist
Tirzepatide (Zepbound)	20.2% vs 13.7% for semaglutide at 72 weeks, 751 adults, open-label (12)	Yes	GIP and GLP-1 receptor agonist

People look at AOD 9604 when GLP-1 drugs cause nausea or cost too much. Neither reason creates evidence that it works. If side effects are the problem, a prescriber can change the dose or the drug. For the wider picture, see our guide to fat loss peptides.

Doses, cycles and stacks

No dose, cycle, timeline or stack has been tested in people for injected AOD 9604, and this page lists none. None of the six trials combined it with another peptide (1).

Quality and sourcing

Quality varies between sellers, and even a clean certificate of analysis only describes one lot. It doesn’t show safety or effect in people. See how to verify a peptide COA, and compare sellers in the best peptide vendors guide.

The bottom line

AOD 9604 is a growth hormone fragment with a short-term safety record from company-run trials and no demonstrated fat-loss benefit. The mechanism is unsettled. It isn’t a substitute for approved treatment.

It’s a poor fit if you expect GLP-1-level weight loss, want a shortcut around diet and exercise, or plan to use it without medical supervision.

Frequently Asked Questions

Is AOD 9604 FDA approved?

No. It isn’t an FDA-approved drug. The developer announced a self-described GRAS designation in 2014 for use as a food and supplement ingredient. That isn’t an FDA approval (9). FDA lists AOD-9604 among withdrawn bulk-drug nominations (7).

Has AOD 9604 been tested orally?

The human trials gave it orally as capsules and tablets and by IV infusion (1). A 2013 news report said the large trial of tablets failed to show it worked (6). Oral peptides also face digestive barriers, which our guide to taking peptides orally explains.

Does AOD 9604 affect blood sugar or insulin?

In the developer’s trials it had no negative effect on glucose tolerance compared with placebo. The longest trial ran 24 weeks (1).

Does WADA ban AOD 9604?

Yes. WADA’s S2 class names AOD-9604 and hGH 176-191 as prohibited growth hormone fragments (10).

Can I use AOD 9604 while taking other medications?

The developer’s safety summary doesn’t report interaction studies (1). Talk to your prescriber before adding any unapproved compound.

Why did AOD 9604 development for obesity stop?

A 2013 news report said the company stopped developing it in 2007 after a large trial of tablets failed to show it worked (6).

This article is for informational purposes only and does not constitute medical advice. AOD 9604 is not FDA-approved for weight loss or any medical condition. Consult a qualified healthcare provider before starting any peptide protocol.